Enterprise Value
97.97M
Cash
89.19M
Avg Qtr Burn
-30.15M
Short % of Float
0.25%
Insider Ownership
0.00%
Institutional Own.
18.39%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OPT-302 Details Wet age-related macular degeneration , Eye disease | Phase 3 Data readout | |
OPT-302 Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |